A theme centered on 4361 advancing its 5-year medium-term management plan, “ACCEL2026,” from the fiscal year ending November 2022 through the fiscal year ending November 2026, with the aim of expanding high-value-added products, contract synthesis products, and products for electronic materials and pharmaceutical applications based on its organic synthesis technology. The final year is positioned as a milestone for achieving its management targets and transitioning to the next plan.